Smith M E, Somera F P, Saldivar R, Massacesi L, Trotter J
J Neurochem. 1984 Dec;43(6):1635-41. doi: 10.1111/j.1471-4159.1984.tb06089.x.
DNA levels were measured in the spinal cords of Lewis rats during the development of and recovery from experimental allergic encephalomyelitis (EAE). Spinal cord DNA was first increased 11 days after immunizing the rats with guinea pig myelin and rose to levels four times that of the Freund's adjuvant controls at day 14, then subsided after day 22. Spinal cord DNA was still 150% of control levels 60 days after immunization. These DNA changes were compared with fluctuations in spinal cord acid proteinase in the same animals. Acid proteinase activity in EAE spinal cord increased later than the rise in DNA and attained a level of 170% of control at days 15-17, then subsided. Spinal cord DNA was higher in rats immunized with whole myelin than in those administered equivalent amounts of purified myelin basic protein. Furthermore DNA was higher in spinal cords of rats immunized with a larger dose of myelin (1.0 mg) than with a lower amount (0.5 mg). Various protease inhibitors including pepstatin, nitrophenyl p-guanidino benzoate, polylysine, and dipropionyl rhein, previously shown to protect Lewis rats against EAE, suppressed the increase of DNA in the spinal cord. Measurement of DNA increases in the spinal cord of EAE animals provides a convenient reproducible measurement of the severity of inflammation in the CNS and provides an objective criterion for assessment of the efficacy of various agents screened as possible therapeutic treatment for multiple sclerosis.
在实验性变应性脑脊髓炎（EAE）的发展及恢复过程中，对Lewis大鼠脊髓中的DNA水平进行了测定。在用豚鼠髓磷脂免疫大鼠11天后，脊髓DNA首先增加，并在第14天升至弗氏佐剂对照组的四倍，然后在第22天后下降。免疫60天后，脊髓DNA仍为对照水平的150%。将这些DNA变化与同一动物脊髓酸性蛋白酶的波动进行了比较。EAE脊髓中的酸性蛋白酶活性比DNA升高出现得晚，在第15 - 17天达到对照水平的170%，然后下降。用全髓磷脂免疫的大鼠脊髓中的DNA高于给予等量纯化髓磷脂碱性蛋白的大鼠。此外，用较大剂量（1.0 mg）髓磷脂免疫的大鼠脊髓中的DNA高于用较低剂量（0.5 mg）免疫的大鼠。先前已证明包括胃蛋白酶抑制剂、对硝基苯基 - p - 胍基苯甲酸酯、聚赖氨酸和二丙酰大黄酸在内的各种蛋白酶抑制剂可保护Lewis大鼠免受EAE侵害，它们抑制了脊髓中DNA的增加。测量EAE动物脊髓中DNA的增加为中枢神经系统炎症严重程度提供了一种方便且可重复的测量方法，并为评估筛选作为多发性硬化症可能治疗方法的各种药物的疗效提供了客观标准。
